Substantial doubt about the company's ability to continue as a going concern.
“Our management concluded that our recurring losses from operations, existing unrestricted cash, and cash equivalents raise substantial doubt about our ability to continue as a going concern for the next twelve months after issuance of our financial statements included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Oct 28, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
DBV filed the Viaskin BLA for children 4 to 7 on September 28th, reporting 47% efficacy versus 14% on placebo at one year; FDA acceptance is expected in late November, while cash runway reaches Q3 of next year.
DBV filed the Viaskin BLA for children 4 to 7 on September 28th, reporting 47% efficacy versus 14% placebo at one year. A toddler BLA is planned, while cash runs into Q3 of next year.
DBV Technologies submitted a BLA for children age 4 through 7 and expects the toddler BLA in 2027. It ended the third quarter with 165.7 million U.S. dollars, funding operations into the third quarter of 2027.
DBV Technologies S.A. submitted the VIASKIN Peanut Patch BLA for children aged 4 through 7 years on September 29, 2026 and requested Priority Review. Third-quarter net loss was $64.5 million, and substantial doubt exists about its ability to continue as a going concern.
DBV Technologies S.A. submitted its BLA for VIASKIN Peanut in children ages 4 through 7 on September 29, 2026, requested Priority Review, and reported a $162.5 million nine-month net loss, $165.7 million cash, and runway into the third quarter of 2027.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DBVT
this stock
DBV Technologies S.A.
|
$692.19M | -42.5% | +35.8% | — | 1.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
DBV filed the Viaskin BLA for children 4 to 7 on September 28th, reporting 47% efficacy versus 14% placebo at one year. A toddler BLA is planned, while cash runs into Q3 of next year.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DBVT | +5.4% | +21.7% | -39.3% | +16.1% | -42.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +2.8% | +22.9% | -39.8% | +16.3% | -53.2% |
